Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 17/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.33 |
| ▸ | PEPD | P12955 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.32 |
| ▸ | FAP | Q12884 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21897066 | 0.91 | PEPD (0.35) | PEPD | |
| SCHEMBL19658043 | 0.85 | DPP8 (0.34) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL22534979 | 0.84 | DPP4 (0.35) | DPP4DPP8DPP7PEPDDPP9 | |
| SCHEMBL19658093 | 0.82 | PIK3CD (0.43) | DPP4DPP8DPP7PEPDDPP9 | |
| SCHEMBL15033782 | 0.82 | PIK3CD (0.43) | DPP4DPP8DPP7PEPDDPP9 | |
| SCHEMBL18994149 | 0.82 | PEPD (0.33) | DPP4PEPD | |
| SCHEMBL19658165 | 0.81 | PEPD (0.35) | PEPD | |
| SCHEMBL21142893 | 0.80 | DPP4 (0.33) | DPP4 | |
| SCHEMBL19658095 | 0.73 | PEPD (0.37) | PEPD | |
| SCHEMBL15396012 | 0.72 | PIK3CD (0.42) | DPP4DPP8DPP7DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10807990-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2020-10-20 | — | — | US | disclosed |
| US-20190276468-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276468-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | DPP4 136/4885DPP8 113/4885DPP7 246/4885 |
| US-10807990-B2 | Antiviral compounds | MAVS, EIF2AK2, SARS1 | DPP4 136/4885DPP8 113/4885DPP7 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.